BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis
Grazia Maria Vernaci(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Cristina Ghiotto(Istituto Oncologico Veneto), Elisabetta Di Liso(Istituti di Ricovero e Cura a Carattere Scientifico), Giulia Tasca(University of Padua), PierFranco Conte(University of Padua), Silvia Michieletto(Istituto Oncologico Veneto), Alice Menichetti(University of Padua), Giovanni Faggioni(Istituto Oncologico Veneto), S. Manfrin(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), Mara Mantiero(University of Padua), Gaia Griguolo(University of North Carolina at Chapel Hill), Tania Saibene(Istituti di Ricovero e Cura a Carattere Scientifico), Eleonora Mioranza(Istituti di Ricovero e Cura a Carattere Scientifico), Cristina Falci(Istituti di Ricovero e Cura a Carattere Scientifico), Federica Miglietta(University of Padua)
Cited by 29
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830